Drugs Made In America Acquisition Corp.
DMAA
$10.33
$0.000.00%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 81.99% | -- | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 81.99% | -- | |||
| Operating Income | -81.99% | -- | |||
| Income Before Tax | 1,607.66% | -- | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 1,607.66% | -- | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 1,607.66% | -- | |||
| EBIT | -81.99% | -- | |||
| EBITDA | -- | -- | |||
| EPS Basic | 485.80% | 2,539.29% | |||
| Normalized Basic EPS | 483.96% | -- | |||
| EPS Diluted | 426.00% | 2,539.29% | |||
| Normalized Diluted EPS | 483.96% | -- | |||
| Average Basic Shares Outstanding | 291.03% | -- | |||
| Average Diluted Shares Outstanding | 291.03% | -- | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||